EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy

Luca Ielasi iD, Bernardo Stefanini iD, Fabio Conti, Matteo Tonnini, Raffaella Tortora, Giulia Magini, Rodolfo Sacco iD, Tiziana Pressiani, Franco Trevisani iD, Francesco Giuseppe Foschi iD, Fabio Piscaglia iD, Alessandro Granito iD und 1 weitere

Current Oncology · 2024

DOI: 10.3390/curroncol31010038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Luca Ielasi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Ospedale degli Infermi di Faenza, 48018 Faenza, Italy. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intermediate-stage hepatocellular carcinoma (BCLC B HCC) occurs in a heterogeneous group of patients and can be addressed with a wide spectrum of treatments. Consequently, survival significantly varies among patients. In recent years, several subclassification systems have been proposed to stratify patients’ prognosis. We analyzed and compared these systems (Bolondi, Yamakado, Kinki, Wang, Lee, and Kim criteria) in patients undergoing systemic therapy.

Methods

We considered 171 patients with BCLC B HCC treated with sorafenib as first-line systemic therapy in six Italian centers from 2010 to 2021 and retrospectively applied the criteria of six different subclassification systems.

Results

Except for the Yamakado criteria, all the subclassification systems showed a statistically significant correlation to overall survival (OS). In the postestimation analysis, the Bolondi criteria (OS of subgroups 22.5, 11.9, and 6.6 mo, respectively; C-index 0.586; AIC 1338; BIC 1344) and the Wang criteria (OS of subgroups 20.6, 11.9, and 7.0, respectively; C-index 0.607; AIC 1337; BIC 1344) presented the best accuracy. Further analyses of these two subclassification systems implemented with the prognostic factor of alpha-fetoprotein (AFP) > 400 ng/mL have shown an increase in accuracy for both systems (C-index 0.599 and 0.624, respectively).

Conclusions

Intermediate-stage subclassification systems maintain their predictive value also in the setting of systemic therapy. The Bolondi and Wang criteria showed the highest accuracy. AFP > 400 ng/mL enhances the performance of these systems.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansalpha-FetoproteinsRetrospective StudiesNeoplasm Staging

Stichwörter der Autor:innen

BCLC BBarcelona Clinic Liver Classificationhepatocellular carcinomaintermediate stagesubclassificationsystemic therapy

Substanzen

alpha-Fetoproteins

Autor:innen und Institutionen

  • Department of Internal Medicine, Ospedale degli Infermi di Faenza, 48018 Faenza, Italy.
  • Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy.
  • Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.
  • Liver Unit, Department of Transplantation, Cardarelli Hospital, 80131 Naples, Italy.
  • Department of Gastroenterology and Transplant Hepatology, Papa Giovanni XXIII Hospital, 24127 Bergamo, Italy.
  • Gastroenterology Unit, Azienda Ospedaliero-Universitaria Pisana, 56126 Pisa, Italy.

ORCID-Profile: Luca Ielasi, Bernardo Stefanini, Rodolfo Sacco, Franco Trevisani, Francesco Giuseppe Foschi, Fabio Piscaglia, Alessandro Granito, Francesco Tovoli

Zitieren

APA

Ielasi, L., Stefanini, B., Conti, F., Tonnini, M., Tortora, R., Magini, G., Sacco, R., Pressiani, T., Trevisani, F., Foschi, F. G., Piscaglia, F., Granito, A., & Tovoli, F. (2024). Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy. Current Oncology. https://doi.org/10.3390/curroncol31010038

Vancouver

Ielasi L, Stefanini B, Conti F, Tonnini M, Tortora R, Magini G, et al. Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy. Current Oncology. 2024. doi:10.3390/curroncol31010038

BibTeX
@article{Ielasi2024,
  author = {Ielasi, Luca and Stefanini, Bernardo and Conti, Fabio and Tonnini, Matteo and Tortora, Raffaella and Magini, Giulia and Sacco, Rodolfo and Pressiani, Tiziana and Trevisani, Franco and Foschi, Francesco Giuseppe and Piscaglia, Fabio and Granito, Alessandro and Tovoli, Francesco},
  title = {Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31010038}
}
Kostenlos starten →